Status:
UNKNOWN
Myopericarditis After Messenger Ribonucleic Acid (mRNA) COVID-19 Vaccination in Children 5-11 Years Old
Lead Sponsor:
Rigshospitalet, Denmark
Collaborating Sponsors:
Innovation Fund Denmark
Ministry of Education, Denmark
Conditions:
Myopericarditis
Myocarditis
Eligibility:
All Genders
5-11 years
Brief Summary
Myopericarditis is a rare complication to messenger ribonucleic acid (mRNA) COVID-19 vaccines, especially in male adolescents and young adults. The risk in children 5-11 years old is unknown. In Denma...
Detailed Description
AIM The project seeks to estimate the incidence of myopericarditis in children 5-11 years old after mRNA COVID-19 vaccination. HYPOTHESIS The incidence of myopericarditis after mRNA COVID-19 vaccinat...
Eligibility Criteria
Inclusion
- Children 5-11 years old hospitalized due to myocarditis and pericarditis following mRNA vaccination
Exclusion
- Viral or bacterial cause of myopericarditis, or other known cause of myopericarditis
Key Trial Info
Start Date :
December 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 28 2022
Estimated Enrollment :
350000 Patients enrolled
Trial Details
Trial ID
NCT05186571
Start Date
December 1 2021
End Date
April 28 2022
Last Update
January 31 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Copenhagen University Hospital, Rigshospitalet
Copenhagen, Denmark, 2100